Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.73 |
| ▸ | HTR7 | P34969 | 2/20 | 0.59 |
| ▸ | HTR1A | P08908 | 6/20 | 0.56 |
| ▸ | HTR2A | P28223 | 4/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2296651 | 0.92 | L3MBTL1 (0.73) | L3MBTL1HTR7HTR1AHTR2AHTR6 | |
| Hydrochloric Acid SCHEMBL2297385 | 0.91 | L3MBTL1 (0.72) | L3MBTL1HTR7HTR1AHTR2AHTR6 | |
| SCHEMBL11159815 | 0.90 | L3MBTL1 (0.70) | L3MBTL1HTR7HTR1AHTR2AHTR6 | |
| SCHEMBL682810 | 0.86 | HTR7 (0.58) | L3MBTL1HTR7HTR6TSHR | |
| SCHEMBL684356 | 0.86 | HTR7 (0.58) | L3MBTL1HTR7HTR6TSHR | |
| SCHEMBL683692 | 0.83 | L3MBTL1 (0.56) | L3MBTL1HTR7HTR1AHTR2A | |
| SCHEMBL683655 | 0.83 | HTR7 (0.77) | L3MBTL1HTR7HTR1AHTR2AHTR6 | |
| SCHEMBL682816 | 0.82 | TSHR (0.55) | L3MBTL1HTR7HTR6TSHR | |
| SCHEMBL683604 | 0.81 | RXFP1 (0.62) | L3MBTL1HTR7HTR6ALOX15TSHR | |
| SCHEMBL683994 | 0.81 | RXFP1 (0.63) | L3MBTL1HTR7HTR1AHTR2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | L3MBTL1 4624/4885HTR7 1398/4885HTR1A 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.